We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$118M
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$180M
AUM Growth
+$35.3M
(+24%)
Cap. Flow
+$33.3M
Cap. Flow
% of AUM
18.49%
Top 10 Holdings %
Top 10 Hldgs %
21.58%
Holding
287
New
78
Increased
46
Reduced
73
Closed
55
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$4.54M |
| 2 |
Coherus Oncology
CHRS
|
+$3.29M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$2.71M |
| 4 |
Embecta
EMBC
|
+$2.55M |
| 5 |
Invesco S&P 500 Pure Value ETF
RPV
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$4.1M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$2.81M |
| 3 |
Invesco NASDAQ 100 ETF
QQQM
|
+$2.81M |
| 4 |
Innoviva
INVA
|
+$2.07M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$1.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.9% |
| 2 | Real Estate | 10.66% |
| 3 | Financials | 4.01% |
| 4 | Technology | 3.46% |
| 5 | Consumer Discretionary | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Globe Life
GL
$13.5B
| $236K | 0.13% |
2,151
-168
| -7% | -$18.1K |
|
127
Boston Scientific
BSX
$65.8B
| $236K | 0.13% |
+4,359
| New | +$228K |
|
128
Jack Henry & Associates
JKHY
$10.7B
| $234K | 0.13% |
1,397
-107
| -7% | -$16.7K |
|
|
MRO
129
DELISTED
Marathon Oil Corporation
MRO
| $234K | 0.13% |
10,154
-477
| -4% | -$11.2K |
|
130
O'Reilly Automotive
ORLY
$72.4B
| $233K | 0.13% |
+3,660
| New | +$223K |
|
131
MGM Resorts International
MGM
$11.7B
| $232K | 0.13% |
+5,290
| New | +$226K |
|
132
AutoZone
AZO
$48.3B
| $232K | 0.13% |
+93
| New | +$237K |
|
133
Valero Energy
VLO
$89.8B
| $228K | 0.13% |
1,940
-1,943
| -50% | -$226K |
|
134
Monster Beverage
MNST
$91.4B
| $226K | 0.13% |
+3,932
| New | +$224K |
|
135
J.M. Smucker
SJM
$12.6B
| $225K | 0.12% |
+1,524
| New | +$232K |
|
136
Mondelez International
MDLZ
$77.7B
| $219K | 0.12% |
+2,999
| New | +$222K |
|
137
Hershey
HSY
$35.4B
| $215K | 0.12% |
862
-266
| -24% | -$69.8K |
|
138
Phillips 66
PSX
$82.9B
| $214K | 0.12% |
2,246
-1,447
| -39% | -$141K |
|
139
Chevron
CVX
$388B
| $211K | 0.12% |
1,343
-61
| -4% | -$9.78K |
|
140
Occidental Petroleum
OXY
$57B
| $209K | 0.12% |
3,555
-2,108
| -37% | -$126K |
|
141
Bristol-Myers Squibb
BMY
$127B
| $208K | 0.12% |
3,248
-231
| -7% | -$15.5K |
|
142
Amgen
AMGN
$203B
| $204K | 0.11% |
918
-64
| -7% | -$14.8K |
|
143
FlexShares High Yield Value-Scored Bond Index Fund
HYGV
$1.09B
| $196K | 0.11% |
+4,838
| New | +$194K |
|
144
iShares Fallen Angels USD Bond ETF
FALN
$1.63B
| $196K | 0.11% |
7,711
+1,382
| +22% | +$34.6K |
|
145
State Street SPDR Bloomberg High Yield Bond ETF
JNK
$7.24B
| $195K | 0.11% |
+2,117
| New | +$194K |
|
146
iShares US & Intl High Yield Corp Bond ETF
GHYG
$184M
| $195K | 0.11% |
4,585
-693
| -13% | -$29.3K |
|
147
iShares 0-5 Year High Yield Corporate Bond ETF
SHYG
$7.57B
| $194K | 0.11% |
4,691
-665
| -12% | -$27.4K |
|
148
Humana
HUM
$46.7B
| $190K | 0.11% |
+425
| New | +$214K |
|
149
Vanguard High Dividend Yield ETF
VYM
$81.1B
| $180K | 0.1% |
+1,697
| New | +$178K |
|
150
APA Corp
APA
$12.8B
| $178K | 0.1% |
5,219
-5,843
| -53% | -$204K |
|
Similar funds
AIS
IVGAI
OIM
TIP
RCG
CWM
SPW
WLC
AlphaCentric Advisors's Q2 2023 Portfolio in Review
As of Q2 2023, AlphaCentric Advisors held 287 positions worth $180M, up 24% from $145M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
AlphaCentric Advisors deployed $33.3M of net new capital in Q2 2023, opening 78 new positions and adding to 46 existing holdings. Its largest new stake was Embecta: 93,500 shares worth $2.02M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was iShares 1-3 Year Treasury Bond ETF, an estimated $4.1M trimmed.
- AlphaCentric Advisors's largest Q2 2023 buy was Embecta: 93,500 shares worth $2.02M.
- AlphaCentric Advisors added most to Jazz Pharmaceuticals in Q2 2023, an estimated $4.54M increase.
- AlphaCentric Advisors's biggest Q2 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $4.1M.
- AlphaCentric Advisors fully exited Invesco QQQ Trust in Q2 2023, selling an estimated $2.81M.
- AlphaCentric Advisors's ten largest holdings make up 22% of its $180M portfolio in Q2 2023.
- AlphaCentric Advisors opened 78 new positions and closed 55 in Q2 2023.
- AlphaCentric Advisors's portfolio value rose 24% quarter-over-quarter to $180M.
Based on AlphaCentric Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.